Develops experimental medicines for patients with inherited disorders, cancers driven by cell-signaling changes, and other diseases, including brain disorders.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies…View ↗
We are advancing a pipeline of two therapeutic product candidates, with a focus on our lead product candidate, PAS-004, a next-generation…View ↗
Our PAS-001 discovery program is in the early stage of development and aims to develop a brain penetrant small molecule targeting the…View ↗
10-Q for Q3 FY2026, filed Nov 13, 2026
−$6.6MView ↗
8-K, filed Aug 21, 2026
On August 20, 2026, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to February…View ↗
Stated focus
The older report focused on central nervous system disorders and RASopathies; the latest describes a focus on RASopathies and MAPK pathway-driven tumors, among other diseases.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 30, 2026We are a biotechnology company primarily focused on the discovery, research and development of innovative treatments for Central Nervous…View ↗
We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies…View ↗
ALS program
The older report described an ALS drug program; the latest says the company stopped its further development.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 30, 2026Our PAS-003 program aims to develop a proprietary humanized monoclonal antibody (“mAb”) with a mechanism-of-action targeting a5b1 integrin…View ↗
During the year ended December 31, 2025, we determined to cease further development of our PAS-003 program for ALS due to several factors…View ↗
Competes with GSK, Novartis, Pfizer, Genentech, Verastem, AstraZeneca, Merck &, SpringWorks Therapeutics, Array BioPharma, Chia Tai Tianqing Pharmaceutical Group, Healx, Infixion Bioscience, Shanghai Fosun Pharmaceutical (Group), Shanghai Kechow Pharma, and NFlection Therapeutics
10-K for FY2025, filed Mar 30, 2026Companies with FDA approved MEK inhibitors include: GSK plc, which received FDA approval for Mekinist (trametinib), that was subsequently…View ↗
Loading...